Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Jon Koplik who wrote (1481)	2/10/1999 11:41:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 2135

Sundeen noted that in 1996, Bristol-Myers quit research into using the controversial drug Thalidomide to help cancer patients. EntreMed went ahead and developed the product and licensed it to Celgene Inc., which received FDA approval last year and has seen strong early sales. Now, that's spin. That's spin ART. Do you suppose it came from Sundeen that way, or that the reporter put it together that way? If it came from Sundeen that way...... tweeeeeeeeet! foul! penalty of $1/share.

To: Jon Koplik who wrote (1481)	2/10/1999 11:42:00 PM
From: David Winkler	Respond to of 2135

money will be scarce unless they get another partner. They may have to continue on their focus on endostatin and hope it works by itself. They have a number of other irons in the fire. Probably too many!! But some of them may be money makers, though they will not get much if they have to dump them early in development. Does a secondary offering seem likely. Not a good time for one that's for sure!!! see yahoo message 5831 more on that tomorrow